Price
No data yet.
Social Signal Score
Analyst Ratings
27 analystsRevenue
$481.00M+1410.06%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Helen I. Torley
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 423
- Beta
- 0.88
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 4.90
Financials
Revenue
$481.00M+1410.1%Net Income
$229.91MEBITDA
$320.00MFree Cash Flow
$236.72MEPS (diluted)
$1.90Shares Outstanding (diluted)
121.22M-5.4%Operating Expenses
$84.66MCash & Debt
$231.00MReturn of Capital
$332.73MRevenue by Segment (annual)
$1.62BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.40B | $316.89M | $2.64 |
| 2024 | $1.02B | $444.09M | $3.50 |
| 2023 | $829.25M | $281.59M | $2.13 |
| 2022 | $660.12M | $202.13M | $1.48 |
| 2021 | $443.31M | $402.71M | $2.86 |
| 2020 | $267.59M | $129.09M | $0.95 |
| 2019 | $195.99M | $-72.24M | $-0.50 |
| 2018 | $151.86M | $-80.33M | $-0.56 |
| 2017 | $316.61M | $62.97M | $0.46 |
| 2016 | $146.69M | $-103.02M | $-0.81 |
| 2015 | $135.06M | $-32.23M | $-0.25 |
| 2014 | $75.33M | $-68.38M | $-0.56 |
| 2013 | $54.80M | $-83.48M | $-0.74 |
| 2012 | $42.33M | $-53.55M | $-0.48 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.89
- Implied price
- $97.13
- Return from $109.86
- -2.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $48.29 — -56.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 21 | 25 | 29 | 33 |
|---|---|---|---|---|---|
| -2.0% | -18.0% | -14.5% | -11.5% | -8.8% | -6.4% |
| 3.0% | -13.9% | -10.1% | -6.9% | -4.1% | -1.6% |
| 8.0% | -9.7% | -5.8% | -2.4% | 0.5% | 3.1% |
| 13.0% | -5.5% | -1.4% | 2.1% | 5.2% | 7.9% |
| 18.0% | -1.3% | 2.9% | 6.6% | 9.8% | 12.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-16.67%Social Signal Score
Mentions (28)
- Newsprnewswire.com·5d ago·Neutral
Halozyme Announces Appointment of Jim Daly to its Board of Directors SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors.
View source ↗ - Newsdefenseworld.net·12d ago·Neutral
Head to Head Review: Halozyme Therapeutics (NASDAQ:HALO) & Co-Diagnostics (NASDAQ:CODX) Halozyme Therapeutics (NASDAQ: HALO - Get Free Report) and Co-Diagnostics (NASDAQ: CODX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Analyst Ratings This is a breakdown of recent ratings
View source ↗ - Newszacks.com·13d ago·Neutral
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength? Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
View source ↗ - News (RSS)seekingalpha·18d ago·Neutral
Halozyme prices $1.3B convertible senior notes offering due 2033
View source ↗ - News (RSS)investing·18d ago·Neutral
Halozyme prices $1.3 billion convertible notes offering
View source ↗ - Newsprnewswire.com·18d ago·Neutral
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the "Convertible Notes").
View source ↗ - Newsprnewswire.com·19d ago·Neutral
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the "Convertible Notes").
View source ↗ - Newszacks.com·19d ago·Neutral
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
View source ↗ - News (RSS)seekingalpha·20d ago·Positive
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsfxempire.com·25d ago·Neutral
Record Revenue Growth Boosts Halozyme Shares Institutions have pushed Halozyme Therapeutics, Inc. (HALO) shares up 769% since March 2014.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Halozyme Therapeutics, Inc. (HALO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Halozyme Therapeutics, Inc. (HALO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·34d ago·Neutral
Halozyme to Participate at Upcoming Investor Conferences SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief Financial Officer, are scheduled to participate and host investor meetings at the following investor conferences.
View source ↗ - Newsseekingalpha.com·35d ago·Negative
…icing The Second Growth Wave Halozyme Therapeutics is evolving into a diversified, high-margin royalty platform, reducing reliance on single assets like DARZALEX SC. HALO delivered 48% YoY revenue growth in 2Q26, with royalty revenue up 50% and EBITDA margins reaching 68%; full-year guidance was raised across all key metrics. Royalty streams are broadening across mature and new products, with sequential growth from recent launches and a robust pipeline targeting launches from 2029 onward.
View source ↗ - Newszacks.com·35d ago·Positive
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes" Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
View source ↗ - Newszacks.com·38d ago·Neutral
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newsfeeds.newsfilecorp.com·40d ago·Neutral
Cleantek Industries Secures Sale of HALO SE Units for Deployment in Alaska Calgary, Alberta--(Newsfile Corp. - August 26, 2026) - Cleantek Industries Inc. (TSXV: CTEK) ("Cleantek" or the "Company"), a leading provider
View source ↗ - Newsseekingalpha.com·43d ago·Positive
Halozyme Therapeutics: Running Through 2027 Halozyme Therapeutics shares have appreciated over 80% since my initial coverage and investment in 2024. My previous articles outlined a bullish investment thesis and detailed expectations for HALO's performance in the current year. HALO's stock performance has delivered significant returns, validating the earlier investment case and strategic positioning.
View source ↗ - Newszacks.com·45d ago·Positive
HALO Stock Rises 36% in a Month: Here's What You Should Know Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.
View source ↗ - Newsprnewswire.com·48d ago·Neutral
Halozyme Appoints Dannielle Appelhans to its Board of Directors SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings more than 20 years of executive leadership across the biotechnology and pharmaceutical industries, with deep expertise in operations, manufacturing, and supply chain management.
View source ↗ - Newsglobenewswire.com·49d ago·Neutral
Sagtec Officially Launches HALO AI and Secures US$3 Million Purchase Order for 1,500 AI Food-Serving Robots from Dubai Distributor Major Commercialization Milestone Expands Sagtec's AI Robotics Platform into the Middle East and Establishes Initial Large-Scale Deployment Major Commercialization Milestone Expands Sagtec's AI Robotics Platform into the Middle East and Establishes Initial Large-Scale Deployment
View source ↗ - 4chan /biz/biz·52d ago·Neutral
>>62594520 I'll probably just go with SCHD it's similar to HALO but with better companies
View source ↗ - 4chan /biz/biz·52d ago·Neutral
>>62594498 Did you hear about the new HALO ETFs? LOHA and HALX HALO = heavy assets low obsolence The idea is these are capital intensive companies, with large real world presences that are difficult to disrupt.
View source ↗ - 4chan /biz/biz·53d ago·Neutral
…raps. So continuing with requirements >must weed out disrupted value traps via whatever means I have some suggestions of how that could be done. Maye it could be a HALO fund, with heavy, capital intensive assets, and big moats. Or whatever. I don't really care how they weed out disrupted value traps, I just want it to. Without actually just buying growth. It has to be value. Another idea, maybe it could be free cash flow. Maybe it could be a combination of things. I don't care. As long as it w…
View source ↗ - News (RSS)marketwatch·53d ago·Neutral
These nontech stocks can ride the AI build-out for years Massive spending on data centers and AI infrastructure can benefit “HALO” companies: hard assets, low obsolescence.
View source ↗ - Newszacks.com·53d ago·Neutral
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
View source ↗ - 4chan /biz/biz·54d ago·Positive
Do you know about the HALO trade? Heavy Assets Low Obsolescence HALO It's become basically the counter AI trade. HALO companies are companies with high capital costs, and heavy assets. And big moats. Like a manufacturing company, like Ford or some s***, or Walmart. It's had a low correlation with the AI trade. There's some new HALO etfs, but they have like 70 bps fees or some s***. I'll show you a HALO ETF with dirt cheap fees. SCHD. It's not a perfect HALO tracker but it's like 90% there. A
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $2.25 per share
Typical surprise +7.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$2.28 vs $1.79beat
- Mon, May 11$1.60 vs $1.55beat
- Tue, Feb 17$-0.24 vs $2.15miss
- Mon, Nov 3$1.72 vs $1.63beat
- Tue, Aug 5$1.54 vs $1.23beat
- Tue, May 6$1.11 vs $0.95beat
Estimates and results for HALO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HALO officers and directors.
- Bought
- —
- Sold
- $23.2m
0 trades
54 trades
- Posard Matthew L.sold
- Posard Matthew L.sold
- Posard Matthew L.sold
- Posard Matthew L.sold
- Posard Matthew L.sold
- Posard Matthew L.sold
- Posard Matthew L.sold
- Posard Matthew L.sold
46 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (30d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 7, 2025 (14d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 3, 2024 (24d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$15,001 - $50,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 13, 2023 (38d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Nov 5, 2020 (14d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 5, 2020 (17d later)Buy$1,001 - $15,000
- Mark Warnersenate · VA · disclosed Dec 8, 2017 (32d later)Sell$500,001 - $1,000,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.